Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04846777 · ClinicalTrials.gov registry record · NA

Brief Smartphone Treatment Study

A NA study of Generalized Anxiety Disorder, sponsored by Penn State University.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT04846777: Recruiting NA study of Generalized Anxiety Disorder, sponsored by Penn State University.

NCT04846777 is a NA study of Generalized Anxiety Disorder that is actively recruiting participants, run by Penn State University. The registered enrollment target is 300 participants, above the 209-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (44% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04846777, a NA study of Generalized Anxiety Disorder, is actively recruiting participants, sponsored by Penn State University.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

Little is known about whether and how brief mindfulness therapies yield clinically beneficial effects. This gap exists despite the rapid growth of smartphone mindfulness applications and presence of mental health treatment gap. Specifically, no prior brief, smartphone mindfulness ecological momentary intervention (MEMI) has targeted generalized anxiety disorder (GAD). Moreover, although theories propose that mindfulness intervention can boost attentional control (AC), executive functioning (EF), perspective-taking, and social cognition skills they have largely gone untested. Thus, this randomized controlled trial (RCT) aims to address these gaps by assessing the efficacy of a 14-day smartphone mindfulness EMI (vs. placebo). Participants with GAD will be randomly assigned to either MEMI or self-monitoring placebo (SMP). Those in treatment will exercise multiple core mindfulness strategies (open monitoring, acceptance, attending to small moments, slowed rhythmic diaphragmatic breathing). Also, those in MEMI will be reminded before bedtime that mindfulness is a lifelong practice. Comparatively, participants assigned to SMP will only be prompted to practice self-monitoring. They will notice their thoughts, rate any distress associated with them, and will not be taught any mindfulness strategies. All prompts will occur 5 times a day, for 14 consecutive days. They will complete self-reports and neuropsychological assessments at pre-, post-, and 1-month follow-up. Multilevel modeling analyses will determine if treatment (vs. self-monitoring placebo (SMP)) produces substantially larger reductions in trait worry and negative perseverative cognitions as well as steeper increases in AC and EF (inhibition, set-shifting, working memory updating). In addition, the investigators hypothesized that MEMI (vs. SMP) would lead to greater increases in performance-based and self-reported trait mindfulness, empathy, and perspective taking. Findings will advance understanding of the effica

Primary Outcome

Generalized Anxiety Disorder Questionnaire-IV (GAD-Q-IV) with categorical ('Yes' for presence and 'No' for absence) and continuous response formats (0 = not at all to 8 = very severely) (Newman et al., 2002) (Item 1 to Item 14 self-report; possible range = 0-12). Generalized Anxiety Disorder Questionnaire-Dimensional (Item 15 to Item 30) with consistent continuous 8-point Likert scale response formats that measures the frequency, intensity, uncontrollability, and degree of excessive worry (e.g.,

Interventions

  • DEVICE Mindfulness ecological momentary intervention
  • DEVICE Self-monitoring placebo

Study Locations (1)

Pennsylvania

  • The Pennsylvania State University - University Park

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2018-11-14
Est. Completion 2023-07-31
Phase NA
Penn State University

219 total trials

What NCT04846777 shows while recruiting

NCT04846777 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 209-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (44% higher).

The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Mindfulness ecological momentary intervention is the first listed.

NCT04846777 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04846777 about?

NCT04846777 is a clinical study titled "Brief Smartphone Treatment Study". Little is known about whether and how brief mindfulness therapies yield clinically beneficial effects. This gap exists despite the rapid growth of smartphone mindfulness applications and presence of mental health treatment gap. Specifically, no prior brief, smartphone mindfulness ecological momentar...

What is the current status of trial NCT04846777?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2018-11-14. Estimated completion is 2023-07-31.

What conditions does trial NCT04846777 study?

This clinical trial studies the following conditions: Generalized Anxiety Disorder.

What interventions are being tested in trial NCT04846777?

The interventions under investigation include: Mindfulness ecological momentary intervention (DEVICE), Self-monitoring placebo (DEVICE).

Who is sponsoring clinical trial NCT04846777?

This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04846777 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Generalized Anxiety Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04846777's enrollment target sits among peer trials

300 11th of 48 higher than 38 of 48 other Generalized Anxiety Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04846777, the US trial registry maintained by the National Library of Medicine. NCT04846777 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.